250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Health Care VC Funds in Denmark

A list of 50 VC funds that invest in Health care startups based in Denmark. We rank investors based on the number of investments they made in Health care companies from Denmark. We update this investor list every month.

Top 50 Health Care VC Funds in Denmark

Investor Health Care Denmark investments
Novo Holdings 27
Vaekstfonden 18
BioInnovation Institute 16
PSV 15
Vaekstfonden 14
Seed Capital 13
Sunstone Life Science Ventures 10
People Ventures 7
Gilde Healthcare 5
VF Venture 4
Oskare Capital 4
RA Capital Management 4
West Hill Capital 4
Sweet Capital 3
Crista Galli Ventures 3
Ysios Capital 3
Sofinnova Partners 3
EIR Ventures 3
HealthCap 3
Innovation Fund Denmark 3
byFounders 3
Wellington Partners 2
Balderton Capital 2
M Ventures 2
Lundbeckfonden Ventures 2
Inventure 2
Crowberry Capital 2
VentureFriends 2
Wellcome Trust 2
Forbion Capital Partners 2
CBC Investment Group 2
Novo Ventures 2
14W 2
Johnson & Johnson Development Corporation 2
CAPNOVA 2
Aescap Venture 2
SOSV 2
Industrifonden 2
Karolinska 2
DSM Venturing 2
Investo Capital 2
Export and Investment Fund 2
Likeminded.vc 1
SR One 1
North-East Family Office 1
Lauxera Capital Partners 1
EQT life science 1
KRING Innovation 1
Biofund 1
Noble Group 1
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 17 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
  • Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
Vaekstfonden VC Fund · Hellerup, Hovedstaden, Denmark
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more
Investment focus
  • Software, Information Technology, SaaS
  • Seed, Funding Round, Pre-Seed
  • Denmark, United States, United Kingdom
Portfolio highlights
  • Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
  • Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
  • kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
BioInnovation Institute VC Fund · Copenhagen, Hovedstaden, Denmark · 17 investments in the past 12 months
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more
Investment focus
  • Biotechnology, Medical, Health Care
  • Convertible Note, Pre-Seed, Debt Financing
  • Denmark, Germany, Switzerland
Portfolio highlights
  • NorFalk — NorFalk rethinks the way to produce surfactants: the active and stabilizing ingredients in household care and personal care consumer products.
  • TriptoBIO — TriptoBIO is developing a platform for producing natural plant compounds that will support the health of our planet. Our goal is to create a future where everyone can benefit from the power of plants, without depleting natural resources. Our first compound will liberate the world from rat poison
  • HHC Medical — HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark.
PSV VC Fund · Lyngby, Hovedstaden, Denmark · 5 investments in the past 12 months
PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.
Show more
Investment focus
  • Software, Information Technology, SaaS
  • Seed, Pre-Seed, Funding Round
  • Denmark, United States, United Kingdom
Portfolio highlights
  • spektr — Explore spektr's tailored compliance automation solutions for KYB monitoring, AML compliance, risk management, and more. Try our no-code, customizable platform for free today!
  • UltiHash — Data powers breakthroughs. UltiHash is the storage foundation to accelerate them: blazing fast, highly efficient, and built for sustainable long-term growth.
  • Yacheng Network — Yacheng Network is a provider of information technology and software services that specializes in offering these services.
Vaekstfonden VC Fund · Hellerup, Hovedstaden, Denmark
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more
Investment focus
  • Software, SaaS, Information Technology
  • Seed, Funding Round, Pre-Seed
  • Denmark, United States, Norway
Portfolio highlights
  • Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
  • Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
  • kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
Seed Capital VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in the past 12 months
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more
Investment focus
  • Software, Health Care, SaaS
  • Seed, Funding Round, Series A
  • Denmark, United States, United Kingdom
Portfolio highlights
  • Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
  • Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
  • Embla — Embla provides an online medical weight loss treatment using prescription drugs and coaching. The company provides patients with evidence-based treatments, digital tools, medication, and coaching to facilitate sustainable weight loss. Embla was founded in 2021 and is headquartered in Copenhagen, Denmark.
Sunstone Life Science Ventures VC Fund · Copenhagen, Hovedstaden, Denmark
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Funding Round, Series B, Series A
  • Denmark, Sweden, Switzerland
Portfolio highlights
  • Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
  • Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
People Ventures VC Fund · Taastrup, Hovedstaden, Denmark · 2 investments in the past 12 months
People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.
Show more
Investment focus
  • Health Care, Internet of Things, Software
  • Seed, Pre-Seed, Series A
  • Denmark, Sweden, United States
Portfolio highlights
  • Uniify — Uniify is a no-code customer onboarding software that makes it fast, easy and secure for financial companies to onboard their customers. Save your business time and money, and build onboarding flows for your customers in minutes instead of months.
  • proemial — Proemial is building an open platform that connects researchers to a larger and more diverse audience through personalized summaries of the latest research papers. The mission is to make it easy to read, discuss, understand and engage with recent discoveries, the researchers that produce them, and the companies that commercialize them.
  • Version Lens — Meet your new Product Management Co-Pilot. Reduce overhead for your product team so you can focus on what truly matters, building outstanding products.
Gilde Healthcare VC Fund · Utrecht, Utrecht, The Netherlands · 5 investments in the past 12 months
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series C, Series B, Series A
  • United States, The Netherlands, Germany
Portfolio highlights
  • Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
VF Venture VC Fund
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more
Investment focus
  • Software, Biotechnology, SaaS
  • Seed, Funding Round, Series A
  • Denmark, United Kingdom, Iceland
Portfolio highlights
  • Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
  • Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
  • Onomondo — Onomondo is a global IoT network. Our IoT SIM and cloud platform future proof your devices with full data transparency, freedom to leave, and no third parties.
Oskare Capital VC Fund · Paris, Ile-de-France, France
Oskare Capital is a venture capital firm.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Seed, Pre-Seed, Series A
  • Italy, Denmark, United Kingdom
Portfolio highlights
  • Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
  • Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
  • Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
RA Capital Management VC Fund · Boston, Massachusetts, United States · 71 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • United States, United Kingdom, China
Portfolio highlights
  • Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
  • MBX Biosciences — Homepage - MBX Biosciences
  • Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
West Hill Capital VC Fund · London, England, United Kingdom
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more
Investment focus
  • Information Technology, Software, Health Care
  • Seed, Funding Round, Series A
  • United Kingdom, Denmark
Portfolio highlights
  • Bioomix — Bioomix is a biotechnology company that develops all-natural microbial products that can help farmers achieve a higher and better yield. It was founded in 2021 and its headquarters is located in Odense, Denmark.
  • ATLANT 3D Nanosystems — Micro and nanodevices are built and tested within days instead of months or years.
  • Formalize — A Whistleblower Software system made for accountants and lawyers that have clients, the whistleblower software system helps businesses implement a compliant solution that is both secure and transparent. their products are reporting links, case management, partner account they have designed a journey that makes feel safe about the process. AWS ishandling the physical security of the infrastructure, whistleblower software takes the shared responsibility of security between our cloud infrastructure and application seriously.
Sweet Capital VC Fund · Stockholm, Stockholms Lan, Sweden
Sweet is the King.com (Candy Crush) founders' evergreen investment fund. We are passionate about funding the next generation of entrepreneurs.
Show more
Investment focus
  • Apps, Software, Mobile
  • Seed, Series A, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Pachama — Harnessing AI to drive carbon capture and protect global forests
  • The Expert — Book consultations with the world's top design experts
  • Masters — Train mind and body on the Masters app with full workout programs designed and run by the world's best athletes. Join today and start training like a pro.
Crista Galli Ventures VC Fund · Copenhagen, Hovedstaden, Denmark · 3 investments in the past 12 months
Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.
Show more
Investment focus
  • Health Care, Wellness, Medical
  • Seed, Pre-Seed, Series A
  • United Kingdom, United States, Sweden
Portfolio highlights
  • Jude — Hey, we're Jude. A healthcare start-up on a mission is to bring bladder care into the mainstream.
  • Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
  • Collective Minds Radiology — Collective Minds® is the new radiology workspace. A cloud-based service for collaboration, consultation and access to new digital tools and expertise. We are building the largest global network of collective and artificial intelligence, with humans and machines.
Ysios Capital VC Fund · San Sebastian, Pais Vasco, Spain · 6 investments in the past 12 months
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • Spain, United States, Switzerland
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
  • Engrail Therapeutics — Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 25 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • deepc — The Radiology AI Platform - Your effortless access to AI
  • Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
  • Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.
EIR Ventures VC Fund · Stockholm, Stockholms Lan, Sweden · 2 investments in the past 12 months
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Seed, Funding Round
  • Denmark, Sweden, United States
Portfolio highlights
  • Henlez — Henlez is a Danish startup company.
  • ArgusEye — ArgusEye - Innovative Sensor Solutions - Real-time monitoring and control of biological systems and processes - Patented sensor technology
  • Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
HealthCap VC Fund · Stockholm, Stockholms Lan, Sweden
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Funding Round
  • United States, Sweden, France
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
  • Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
Innovation Fund Denmark VC Fund · Copenhagen, Hovedstaden, Denmark
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more
Investment focus
  • Software, SaaS, Information Technology
  • Grant, Pre-Seed, Seed
  • Denmark, United States
Portfolio highlights
  • Artelize — Discover events, performers and works within classical music, opera, musical, ballet & dance and drama. 174248 events, and 59606 artists and creators.
  • Tryp.com — There is always a reason to go! We use artificial intelligence to find the best travel deals at the lowest price. The algorithm compares and connects flights, trains, and buses to create the perfect multidestination trips with matching hotel offers.
  • Curvature AI — Grow your revenue with discounts and special offers selected and optimized by AI.
byFounders VC Fund · Copenhagen, Hovedstaden, Denmark · 6 investments in the past 12 months
byFounders is the community-powered early-stage venture fund investing in globally ambitious teams connected to the Nordic and Baltic countries. With its unique Collective of founders and operators, byFounders offers its portfolio operational expertise and a global network. Believing in the power of tech to shape our future, byFounders takes an impact-aware approach to investing and working with the broader startup ecosystem.
Show more
Investment focus
  • Software, Artificial Intelligence, SaaS
  • Seed, Series A, Pre-Seed
  • Denmark, United States, Sweden
Portfolio highlights
  • Monta — Monta is the ultimate platform powering the entire EV charging ecosystem. From drivers, to businesses, to industry partners, we offer software solutions that cover all EV charging needs.
  • QA.tech — Our AI combines the skills of a QA engineer with the speed of automated testing for you. This shortens your time to market, cuts costs and improves the quality of your web apps.
  • Dusk — Rune is an automated friend or squad finder and voice chat for players on mobile games. Users can hang out and share amazing experiences together. The company builds the future of LFG for mobile gamers.
Wellington Partners VC Fund · Munich, Bayern, Germany · 3 investments in the past 12 months
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series A, Series B, Funding Round
  • Germany, United States, United Kingdom
Portfolio highlights
  • UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
  • Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.
  • Onward — Working to restore movement, independence, and health in people with spinal cord injury.
Balderton Capital VC Fund · London, England, United Kingdom · 18 investments in the past 12 months
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more
Investment focus
  • Software, FinTech, Financial Services
  • Series B, Series A, Series C
  • United Kingdom, United States, Germany
Portfolio highlights
  • Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
  • Tinybird — Tinybird helps data teams build real-time Data Products at scale through SQL-based API endpoints. It ingests millions of rows per second and serves low latency, high concurrency analytical queries over any amount of data.
  • ZOE — ZOE analyzes your unique gut, blood fat and blood sugar responses. So you can take back control of your health & weight
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 15 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
  • Outrun TX — Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
  • Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Lundbeckfonden Ventures VC Fund · Copenhagen, Hovedstaden, Denmark
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, France
Portfolio highlights
  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
  • LEXEO Therapeutics — LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Inventure VC Fund · Helsinki, Southern Finland, Finland · 6 investments in the past 12 months
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Series A, Series B
  • Finland, Sweden, Denmark
Portfolio highlights
  • Leya AI — Feel and sound like an English native in 3 months
  • Steep — Business intelligence for modern companies. Steep lets anyone on your team stay on top of your data.
  • Reveel — Say goodbye to paper maps, brochures, and outdated audio guides. Reveel offers digital solutions for destinations such as UNESCO sites, sights, museums, cities, hotels and parks, taking the visitor experience to the next level. Become part of the smart destination movement, enhance the visitor experience, and discover the future of travel.
Crowberry Capital VC Fund · Reykjavík, Gullbringusysla, Iceland · 7 investments in the past 12 months
Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.
Show more
Investment focus
  • Software, Information Technology, Gaming
  • Seed, Series A, Pre-Seed
  • Iceland, Denmark, Finland
Portfolio highlights
  • Saidot — Saidot is a governance tool for safe, ethical and transparent AI.
  • Social First — We create games that are social experiences, span decades and extend beyond gaming; giving our players platforms to create meaningful relationships with people all across the world.
  • Scaleup Finance — Improve your financial management
VentureFriends VC Fund · Athens, Attiki, Greece · 6 investments in the past 12 months
We are an early stage investor investing in Seed and Series A startups.
Show more
Investment focus
  • FinTech, E-Commerce, Software
  • Seed, Series A, Funding Round
  • Greece, United Kingdom, United States
Portfolio highlights
  • Cube AI — Cube AI boosts back-office logistics efficiency, allowing teams to handle more loads and focus on human relationships.
  • MoneyHash — MoneyHash provides access to payment and fintech services across the Middle East & Africa with one simple integration.
  • Harbor Lab — Designed to streamline the port cost management processes and optimize operational efficiency for cargo operations and husbandry services by leveraging technology and automation.
Wellcome Trust VC Fund · London, England, United Kingdom
Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Grant, Series C, Funding Round
  • United States, United Kingdom, Germany
Portfolio highlights
  • Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
  • DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
  • Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
Forbion Capital Partners VC Fund · Naarden, Noord-Holland, The Netherlands · 12 investments in the past 12 months
Impacting the future of medicine.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, United Kingdom, The Netherlands
Portfolio highlights
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
  • Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
CBC Investment Group VC Fund · Gothenburg, Vastra Gotaland, Sweden
CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.
Show more
Investment focus
  • Biotechnology, Software, SaaS
  • Funding Round, Seed, Series B
  • Sweden, Denmark, Germany
Portfolio highlights
  • GLX Analytix — GLX Analytix is ​​a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
  • Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
  • Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.
Novo Ventures VC Fund · Bagsværd, Hovedstaden, Denmark
Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established in 1999 prior to the demerger of Novo NordiskA/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.Novo A/S attains these objectives through:compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • INBRACE — Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
  • Theraxyte — Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs.
  • Amolyt Pharma — We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
14W VC Fund · New York, New York, United States · 2 investments in the past 12 months
14W is a Venture Capital firm based in New York, focusing on the intersection of technology and consumer behaviour.
Show more
Investment focus
  • E-Commerce, Fashion, Health Care
  • Seed, Series A, Series B
  • United States, United Kingdom, Spain
Portfolio highlights
  • Exoticca — Exoticca develops an online platform intended to facilitate travel booking. The company's platform offers holiday packages which includes flights, accommodation, meals, guides and private transports, for exotic locations all around the world, enabling travelers to book travel packages online at competitive prices.
  • Cayena — Cayena is a B2B marketplace for the $100b+ wholesale food industry in Latin America. The company allows restaurants, bars, bakeries, hotels and dark kitchens to procure their inventory from multiple suppliers with next day delivery and a comprehensive suite of add-on services.
  • Power Life Science — Discover cutting-edge therapies by enrolling in clinical trials. Power helps patients everywhere take control of their care.
Johnson & Johnson Development Corporation VC Fund · New Brunswick, New Jersey, United States
JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series C, Series B, Funding Round
  • United States, United Kingdom, Canada
Portfolio highlights
  • CVRx — CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
  • Binx Health — Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer
  • Osteal Therapeutics — Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
CAPNOVA VC Fund · Aarhus, Midtjylland, Denmark
They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Funding Round, Seed, Pre-Seed
  • Denmark, United States, India
Portfolio highlights
  • Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
  • Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
  • ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.
Aescap Venture VC Fund · Amsterdam, Noord-Holland, The Netherlands
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more
Investment focus
  • Biotechnology, Pharmaceutical, Chemical
  • Series A, Series B, Funding Round
  • United Kingdom, Austria, Belgium
Portfolio highlights
  • Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
  • Avantium — Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations.
  • F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
SOSV VC Fund · Princeton, New Jersey, United States · 95 investments in the past 12 months
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Seed, Convertible Note, Pre-Seed
  • United States, India, United Kingdom
Portfolio highlights
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
  • Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators
Industrifonden VC Fund · Stockholm, Stockholms Lan, Sweden · 6 investments in the past 12 months
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more
Investment focus
  • Software, Biotechnology, Information Technology
  • Funding Round, Series A, Seed
  • Sweden, United States, Denmark
Portfolio highlights
  • Arevo — Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.
  • Telness Tech — We help telcos maximize customer happiness and minimize OPEX through automation. Our proprietary, cloud-based, end-to-end BSS/OSS platform is connectivity ready in 64 countries.
  • ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.
Karolinska VC Fund · Solna, Stockholms Lan, Sweden
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Funding Round, Seed, Series A
  • Sweden, Denmark, United States
Portfolio highlights
  • PharmNovo — Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.
  • OssDsign AB — Giving patients back the life they deserve, Catalyst nanosynthetic bone graft, orthobiologics
  • Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
DSM Venturing VC Fund · Heerlen, Limburg, The Netherlands · 3 investments in the past 12 months
DSM Venturing provides start-up funding, coaching and support for start-up companies that share our purpose of creating brighter lives for all.
Show more
Investment focus
  • Biotechnology, Health Care, Manufacturing
  • Series A, Funding Round, Series B
  • United States, Canada, Israel
Portfolio highlights
  • Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
  • NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
  • Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
Investo Capital VC Fund · Aalborg, Nordjylland, Denmark
Investo Capital is a Danish venture capital firm based in Aalborg. They invest in carefully selected Danish early-growth companies within tech business areas in the broad sense. The target group is innovative companies with proof of business, strategic thinking, and strong growth prospects in Denmark. Strategic corporate concepts and competentmanagement are essential features. The investment focus is Technology, IT, SAAS- and med-tech.
Show more
Investment focus
  • Health Diagnostics, Computer, Software
  • Seed
  • Denmark
Portfolio highlights
  • Tentoma — Professional packaging machines. Horizontal stretch film packaging machines and innovative industrial wrapping and packaging equipment.
  • Create it REAL — Tailored 3D printing solutions. We help you to get and control material, software, and 3D printers to start a 3D printed production unit.
  • Brainreader — Volumetric brain assessment software for detection of brain atrophies & abnormalities. In depth analysis of brain MRI. Contact Brainreader.
Export and Investment Fund VC Fund · Hellerup, Hovedstaden, Denmark · 14 investments in the past 12 months
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more
Investment focus
  • Software, Health Care, SaaS
  • Seed, Funding Round, Series A
  • Denmark, Ukraine, United States
Portfolio highlights
  • Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
  • EvodiaBio — EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region.
  • Again — SecondCircle makes carbon negative chemicals for a cleaner future. We are the first carbon negative chemical manufacturer that can scale to meet global demand. The best thing about it: we use carbon dioxide as a feedstock.
Likeminded.vc VC Fund · Vedbæk, Hovedstaden, Denmark
Co-investing in tech start-ups with other likeminded business angels in our newly founded micro VC. All of us have a background as founders ourselves bringing our mindset and experience closer to the people we invest in.
Show more
Investment focus
  • Software, Analytics, Health Care
  • Seed, Pre-Seed
  • Denmark, United States
Portfolio highlights
  • Strise — Strise is signaling a new era of enterprise software and organizational change, transforming how companies work and empowering individual growth through knowledge. We believe in the AI-enabled financial institution without data silos where users and data are working together to solve even the most complex business problems.
  • NordInsight — NordInsight is a browser-based implant database, you can reduce the risk to MRI scan patients. Scan confidently alongside renowned medical facilities throughout the globe.
SR One VC Fund · Cambridge, Massachusetts, United States · 8 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
  • Avalyn Pharma — This does NOT display on the home page
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
North-East Family Office VC Fund · Hellerup, Hovedstaden, Denmark
North-East is an ambitious, global family office helping our families live with wealth in a meaningful way from our offices in Denmark and Singapore.
Show more
Investment focus
  • Health Care, Biotechnology, Food Processing
  • Seed, Pre-Seed, Series A
  • Denmark, United States
Portfolio highlights
  • Endless West — Endless West is a beverage startup using scientific production methods to create its own original blend of wines and spirits. Its winery uses molecules from plants, animals, and substances for taste, smell, and color and combines them to create sustainable wine without any grapes, yeast, or any kind of fermentation. The company's firstproduct, Glyph, is the first aged-style spirit made using flavor and aroma molecules extracted from more efficient sources in nature. Glyph is made without aging or barreling which means significantly less wood, water, and land is used in its production process.Endless West was founded in 2015 and is headquartered in San Francisco, California.
  • Reel Energy — Accelerate the transition to a society powered 100% by renewables. Reduce your company's carbon footprint with electricity from new solar parks and wind farms.
  • SNIPR Biome — We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
Lauxera Capital Partners VC Fund · Paris, Ile-de-France, France · 3 investments in the past 12 months
We are an independent, international, healthcare-focused asset management company. Led by entrepreneurial company builders and seasoned healthcare investors with experience across international markets, we invest in Healthcare growth capital and Healthcare public equities.
Show more
Investment focus
  • Biotechnology, Medical Device, Computer
  • Series A, Series C, Series D
  • France, Sweden, Denmark
Portfolio highlights
  • BioLamina — BioLamina offers laminin cell culture matrix, the only laminins that are the original, full length, human recombinant laminins on the market.
  • Jiaozhiwu — Jiaozhiwu is a food-tech brand that specializes in the research and development of synthetic biology in functional food ingredients and nutritional health products.
  • Natural Cycles — Natural Cycles birth control is 93% effective with typical use and 98% effective with perfect use. Learn more about hormone-free birth control today.
EQT life science VC Fund · Amsterdam, Noord-Holland, The Netherlands · 7 investments in the past 12 months
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland
Portfolio highlights
  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
KRING Innovation VC Fund · Copenhagen, Hovedstaden, Denmark
KRING is a venture studio and venture capital fund that exists to bring together exceptional founders and big ideas to create impact ventures
Show more
Investment focus
  • Hospital, Health Care
  • Pre-Seed
  • Denmark
Portfolio highlights
  • Triba Health — Triba Health helps people with Type 2 Diabetes by removing the "chronic" from Type 2 Diabetes Management.
Biofund VC Fund · Siena, Toscana, Italy
BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.
Show more
Investment focus
  • Genetics, Medical, Health Care
  • Funding Round, Seed
  • Canada, Denmark, Russian Federation
Portfolio highlights
  • Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
  • RTM Diagnostika — Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer.
  • Genizon BioSciences — Since 2005, we have helped thousands of people get the perfect domain name.
Noble Group VC Fund · Wan Chai, Hong Kong Island, Hong Kong
Noble Group is a global supply chain manager of energy, power & gas products, metals and carbon steel materials, with interests in key facilities that add value at various stages of its supply chains. Noble Group manages a diversified portfolio of essential natural resources, with integrated sourcing, marketing, processing, financing andtransportation operations. Noble Group's Energy segment encompasses a portfolio of oil liquids and coal products and continues to be a significant driver for the Group’s growth. Gas & Power segment includes their retail energy business Noble Americas Energy Solutions and Gas & Power wholesale operations. In Metals & Mining, Noble Group is one of the world’s leading suppliers with interests in iron ore, aluminium, special ores and alloys across key global locations. The Corporate segment incorporates the Logistics business as well as investments in their major associates. Noble Group (SGX: N21) manages a portfolio of global supply chains covering a range of industrial and energy products. Operating from over 60 locations, Noble facilitates the marketing, processing, financing and transportation of essential raw materials. Sourcing bulk commodities from low cost regions such as South America, South Africa, Australia and Indonesia, the Group supplies high growth demand markets, particularly in Asia and the Middle East. Noble Group is ranked number 77 in the 2015 Fortune Global 500. Noble moves essential resources from producers to consumer across the world. Noble Group's success relies on a rigorously managed balance sheet, effective partnerships and a deep understanding of customer needs. Noble’s core strategy is to be the best company in the world at moving the physical commodity from the producer to the consumer and managing the market, credit and operational risk associated with that. Noble Group's solid financial position comes from a rigorously managed balance sheet with exceptional liquidity and a carefully guided exposure to risk - underpinned by deep relationships with global capital providers. At Noble, they have forged some of the most productive and enterprising partnerships in the industry and they have always believed that as their partners grow, so do they. Noble Group put energy and focus into staying relevant and being valuable to their customers, keeping their interests firmly integrated into their DNA.
Show more
Investment focus
  • Medical, Health Care, Professional Services
  • Funding Round
  • United Kingdom
Portfolio highlights
  • Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
  • Digital-Healthcare — Digital Healthcare is a health care company. The company has been acquired by EMIS Group.
Investors by industry
Investors by country
VC Funds in Denmark by industry